Moderna (MRNA) Stock Price, Fundamentals & Analysis

What MRNA does

Moderna (MRNA) is a biotechnology stock in the Healthcare sector that develops messenger RNA medicines. Its portfolio includes respiratory vaccines such as Spikevax, RSV, and seasonal influenza shots, as well as latent vaccines for cytomegalovirus, Epstein-Barr virus, and HIV, plus oncology therapeutics and rare disease products. It is part of the S&P 500 and has partnerships with companies like Thermo Fisher Scientific (TMO), Johnson & Johnson (JNJ), and Regeneron Pharmaceuticals (REGN).

Key numbers explained

• 182.11 USD is the current share price, the amount you pay for one share today.
• -0.25% is the price change today, showing the stock is down slightly on the session.
• 72.7B USD is the market capitalisation, the total value of all outstanding shares.
• The forward P/E ratio of -40.8 is based on expected future earnings; a negative value means the market expects losses.
• Earnings per share (trailing 12 months) is -8.42 USD, indicating the company lost money over the past year.
• 0% is the dividend yield, meaning Moderna pays no cash dividend to shareholders.
• 1.11 is the beta, a measure of volatility relative to the market; 1.11 suggests slightly above-average price swings.
• 22.28 – 192.31 is the 52-week price range, showing the lowest and highest traded prices in the past year.
• 605.4% is the price change over the last 52 weeks, reflecting a large increase from one year ago.
• -141.4% is the profit margin, a negative figure that means costs exceed revenue.
• 10.75 is the price-to-book ratio, comparing the share price to the company's book value per share.

Recent news

• Moderna stock hit a new high as the CEO said the company is more than Covid vaccines.
• Analysts highlighted Moderna among stocks bucking the broader market selloff to hit new multi-year highs.
• Moderna is eyeing a cancer vaccine filing as it expands beyond Covid.

What to watch

Investors in Moderna typically monitor pipeline progress across respiratory, latent, oncology, and rare disease programs, as well as collaboration updates with partners such as Merck, Vertex, and the Bill & Melinda Gates Foundation. Regulatory decisions, trial results, and broader biotech sentiment also move stocks like this, which is why many compare it with peers such as Illumina, Inc. (ILMN), Cardinal Health (CAH), Gilead Sciences (GILD), and Amgen (AMGN).